Lehrke Michael, Becker Alexander, Greif Martin, Stark Renee, Laubender Rüdiger P, von Ziegler Franz, Lebherz Corinna, Tittus Janine, Reiser Maximilian, Becker Christoph, Göke Burkhard, Leber Alexander W, Parhofer Klaus G, Broedl Uli C
Department of Internal Medicine II, University of Munich, Campus Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany.
Eur J Endocrinol. 2009 Aug;161(2):339-44. doi: 10.1530/EJE-09-0380. Epub 2009 Jun 4.
Chemerin is a recently discovered adipokine that regulates adipocyte differentiation and modulates chemotaxis and activation of dendritic cells and macrophages. Given the convergence of adipocyte and macrophage function, chemerin may provide an interesting link between obesity, inflammation and atherosclerosis in humans. We sought to examine the relationship of i) chemerin and markers of inflammation, ii) chemerin and components of the metabolic syndrome, and iii) chemerin and coronary atherosclerotic plaque burden and morphology.
Serum chemerin levels were determined in 303 patients with stable typical or atypical chest pain who underwent dual-source multi-slice CT-angiography to exclude coronary artery stenosis. Atherosclerotic plaques were classified as calcified, mixed, or non-calcified.
Chemerin levels were highly correlated with high sensitivity C-reactive protein (r=0.44, P<0.0001), interleukin-6 (r=0.18, P=0.002), tumor necrosis factor-alpha (r=0.24, P<0.0001), resistin (r=0.28, P<0.0001), and leptin (r=0.36, P<0.0001) concentrations. Furthermore, chemerin was associated with components of the metabolic syndrome including body mass index (r=0.23, P=0.0002), triglycerides (r=0.29, P<0.0001), HDL-cholesterol (r=-0.18, P=0.003), and hypertension (P<0.0001). In bivariate analysis, chemerin levels were weakly correlated with coronary plaque burden (r=0.16, P=0.006) and the number of non-calcified plaques (r=0.14, P=0.02). These associations, however, were lost after adjusting for established cardiovascular risk factors (odds ratio, OR 1.17, 95% confidence interval (CI) 0.97-1.41, P=0.11 for coronary plaque burden; OR 1.06, 95% CI 0.96-1.17, P=0.22 for non-calcified plaques).
Chemerin is strongly associated with markers of inflammation and components of the metabolic syndrome. However, chemerin does not predict coronary atherosclerosis.
chemerin是一种最近发现的脂肪因子，可调节脂肪细胞分化，并调节树突状细胞和巨噬细胞的趋化性及激活。鉴于脂肪细胞和巨噬细胞功能的趋同，chemerin可能为人类肥胖、炎症和动脉粥样硬化之间提供一个有趣的联系。我们试图研究：i）chemerin与炎症标志物的关系；ii）chemerin与代谢综合征各组分的关系；iii）chemerin与冠状动脉粥样硬化斑块负荷及形态的关系。
对303例有稳定典型或非典型胸痛的患者测定血清chemerin水平，这些患者接受双源多层CT血管造影以排除冠状动脉狭窄。动脉粥样硬化斑块分为钙化斑块、混合斑块或非钙化斑块。
chemerin水平与高敏C反应蛋白（r = 0.44，P < 0.0001）、白细胞介素-6（r = 0.18，P = 0.002）、肿瘤坏死因子-α（r = 0.24，P < 0.0001）、抵抗素（r = 0.28，P < 0.0001）及瘦素（r = 0.36，P < 0.0001）浓度高度相关。此外，chemerin与代谢综合征各组分相关，包括体重指数（r = 0.23，P = 0.0002）、甘油三酯（r = 0.29，P < 0.0001）、高密度脂蛋白胆固醇（r = -0.18，P = 0.003）及高血压（P < 0.0001）。在双变量分析中，chemerin水平与冠状动脉斑块负荷（r = 0.16，P = 0.006）及非钙化斑块数量（r = 0.14，P = 0.02）弱相关。然而，在校正已确定的心血管危险因素后，这些相关性消失（冠状动脉斑块负荷的比值比，OR 1.17，95%置信区间（CI）0.97 - 1.41，P = 0.11；非钙化斑块的OR 1.06，95% CI 0.96 - 1.17，P = 0.22）。
chemerin与炎症标志物及代谢综合征各组分密切相关。然而，chemerin不能预测冠状动脉粥样硬化。
